Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. / Munthe, Sune; Petterson, Stine Asferg; Dahlrot, Rikke Hedegaard; Poulsen, Frantz Rom; Hansen, Steinbjørn; Kristensen, Bjarne Winther.

I: PLoS One, Bind 11, Nr. 5, 2016, s. e0155106.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Munthe, S, Petterson, SA, Dahlrot, RH, Poulsen, FR, Hansen, S & Kristensen, BW 2016, 'Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype', PLoS One, bind 11, nr. 5, s. e0155106. https://doi.org/10.1371/journal.pone.0155106

APA

Munthe, S., Petterson, S. A., Dahlrot, R. H., Poulsen, F. R., Hansen, S., & Kristensen, B. W. (2016). Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. PLoS One, 11(5), e0155106. https://doi.org/10.1371/journal.pone.0155106

Vancouver

Munthe S, Petterson SA, Dahlrot RH, Poulsen FR, Hansen S, Kristensen BW. Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. PLoS One. 2016;11(5):e0155106. https://doi.org/10.1371/journal.pone.0155106

Author

Munthe, Sune ; Petterson, Stine Asferg ; Dahlrot, Rikke Hedegaard ; Poulsen, Frantz Rom ; Hansen, Steinbjørn ; Kristensen, Bjarne Winther. / Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. I: PLoS One. 2016 ; Bind 11, Nr. 5. s. e0155106.

Bibtex

@article{43eee923c94042958d6154ec1d95c957,
title = "Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype",
abstract = "Gliomas are highly infiltrative tumors incurable with surgery. Although surgery removes the bulk tumor, tumor cells in the periphery are left behind resulting in tumor relapses. The aim of the present study was to characterize the phenotype of tumor cells in the periphery focusing on tumor stemness, proliferation and chemo-resistance. This was investigated in situ in patient glioma tissue as well as in orthotopic glioblastoma xenografts. We identified 26 gliomas having the R132 mutation in Isocitrate DeHydrogenase 1 (mIDH1). A double immunofluorescence approach identifying mIDH1 positive tumor cells and a panel of markers was used. The panel comprised of six stem cell-related markers (CD133, Musashi-1, Bmi-1, Sox-2, Nestin and Glut-3), a proliferation marker (Ki-67) as well as a chemo-resistance marker (MGMT). Computer-based automated classifiers were designed to measure the mIDH1 positive nucleus area-fraction of the chosen markers. Moreover, orthotopic glioblastoma xenografts from five different patient-derived spheroid cultures were obtained and the tumor cells identified by human specific immunohistochemical markers. The results showed that tumor cells in the periphery of patient gliomas expressed stem cell markers, however for most markers at a significantly lower level than in the tumor core. The Ki-67 level was slightly reduced in the periphery, whereas the MGMT level was similar. In orthotopic glioblastoma xenografts all markers showed similar levels in the core and periphery. In conclusion tumor cells in the periphery of patient gliomas have a stem cell phenotype, although it is less pronounced than in the tumor core. Novel therapies aiming at preventing recurrence should therefore take tumor stemness into account. Migrating cells in orthotopic glioblastoma xenografts preserve expression and stem cell markers. The orthotopic model therefore has a promising translational potential.",
author = "Sune Munthe and Petterson, {Stine Asferg} and Dahlrot, {Rikke Hedegaard} and Poulsen, {Frantz Rom} and Steinbj{\o}rn Hansen and Kristensen, {Bjarne Winther}",
year = "2016",
doi = "10.1371/journal.pone.0155106",
language = "English",
volume = "11",
pages = "e0155106",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

RIS

TY - JOUR

T1 - Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype

AU - Munthe, Sune

AU - Petterson, Stine Asferg

AU - Dahlrot, Rikke Hedegaard

AU - Poulsen, Frantz Rom

AU - Hansen, Steinbjørn

AU - Kristensen, Bjarne Winther

PY - 2016

Y1 - 2016

N2 - Gliomas are highly infiltrative tumors incurable with surgery. Although surgery removes the bulk tumor, tumor cells in the periphery are left behind resulting in tumor relapses. The aim of the present study was to characterize the phenotype of tumor cells in the periphery focusing on tumor stemness, proliferation and chemo-resistance. This was investigated in situ in patient glioma tissue as well as in orthotopic glioblastoma xenografts. We identified 26 gliomas having the R132 mutation in Isocitrate DeHydrogenase 1 (mIDH1). A double immunofluorescence approach identifying mIDH1 positive tumor cells and a panel of markers was used. The panel comprised of six stem cell-related markers (CD133, Musashi-1, Bmi-1, Sox-2, Nestin and Glut-3), a proliferation marker (Ki-67) as well as a chemo-resistance marker (MGMT). Computer-based automated classifiers were designed to measure the mIDH1 positive nucleus area-fraction of the chosen markers. Moreover, orthotopic glioblastoma xenografts from five different patient-derived spheroid cultures were obtained and the tumor cells identified by human specific immunohistochemical markers. The results showed that tumor cells in the periphery of patient gliomas expressed stem cell markers, however for most markers at a significantly lower level than in the tumor core. The Ki-67 level was slightly reduced in the periphery, whereas the MGMT level was similar. In orthotopic glioblastoma xenografts all markers showed similar levels in the core and periphery. In conclusion tumor cells in the periphery of patient gliomas have a stem cell phenotype, although it is less pronounced than in the tumor core. Novel therapies aiming at preventing recurrence should therefore take tumor stemness into account. Migrating cells in orthotopic glioblastoma xenografts preserve expression and stem cell markers. The orthotopic model therefore has a promising translational potential.

AB - Gliomas are highly infiltrative tumors incurable with surgery. Although surgery removes the bulk tumor, tumor cells in the periphery are left behind resulting in tumor relapses. The aim of the present study was to characterize the phenotype of tumor cells in the periphery focusing on tumor stemness, proliferation and chemo-resistance. This was investigated in situ in patient glioma tissue as well as in orthotopic glioblastoma xenografts. We identified 26 gliomas having the R132 mutation in Isocitrate DeHydrogenase 1 (mIDH1). A double immunofluorescence approach identifying mIDH1 positive tumor cells and a panel of markers was used. The panel comprised of six stem cell-related markers (CD133, Musashi-1, Bmi-1, Sox-2, Nestin and Glut-3), a proliferation marker (Ki-67) as well as a chemo-resistance marker (MGMT). Computer-based automated classifiers were designed to measure the mIDH1 positive nucleus area-fraction of the chosen markers. Moreover, orthotopic glioblastoma xenografts from five different patient-derived spheroid cultures were obtained and the tumor cells identified by human specific immunohistochemical markers. The results showed that tumor cells in the periphery of patient gliomas expressed stem cell markers, however for most markers at a significantly lower level than in the tumor core. The Ki-67 level was slightly reduced in the periphery, whereas the MGMT level was similar. In orthotopic glioblastoma xenografts all markers showed similar levels in the core and periphery. In conclusion tumor cells in the periphery of patient gliomas have a stem cell phenotype, although it is less pronounced than in the tumor core. Novel therapies aiming at preventing recurrence should therefore take tumor stemness into account. Migrating cells in orthotopic glioblastoma xenografts preserve expression and stem cell markers. The orthotopic model therefore has a promising translational potential.

U2 - 10.1371/journal.pone.0155106

DO - 10.1371/journal.pone.0155106

M3 - Journal article

C2 - 27171431

VL - 11

SP - e0155106

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 5

ER -

ID: 364506685